Real Time Insider Transaction Data
Real Time Insider buys and sells Data - Insider Trades - Insider Transactions - Insider Trading Data - SEC Form 4 Data
Total | Transactions | Amount |
Buys | 24 | $4,920,621 |
Sells | 22 | $13,363,226 |
Security | Reporting Name | Relationship | Purchase/Sale | Shares | Price $ | D/I | ||||
09 Aug 2024 16:30 | GLYC | GLYCOMIMETICS INC | INVUS PUBLIC EQUITIES, L.P. | 10% | 08 Aug 2024 | Sale | 260,873 | 0.1917 | 50,009 | D |
09 Aug 2024 16:30 | GLYC | GLYCOMIMETICS INC | INVUS PUBLIC EQUITIES, L.P. | 10% | 07 Aug 2024 | Sale | 61,488 | 0.1821 | 11,197 | D |
07 Aug 2024 16:30 | GLYC | GLYCOMIMETICS INC | INVUS PUBLIC EQUITIES, L.P. | 10% | 06 Aug 2024 | Sale | 55,732 | 0.1828 | 10,188 | D |
07 Aug 2024 16:30 | GLYC | GLYCOMIMETICS INC | INVUS PUBLIC EQUITIES, L.P. | 10% | 05 Aug 2024 | Sale | 164,523 | 0.1884 | 30,996 | D |
05 Aug 2024 16:53 | GLYC | GLYCOMIMETICS INC | INVUS PUBLIC EQUITIES, L.P. | 10% | 02 Aug 2024 | Sale | 286,200 | 0.2004 | 57,354 | D |
05 Aug 2024 16:53 | GLYC | GLYCOMIMETICS INC | INVUS PUBLIC EQUITIES, L.P. | 10% | 01 Aug 2024 | Sale | 63,564 | 0.2162 | 13,743 | D |
30 Jul 2024 17:16 | GLYC | GLYCOMIMETICS INC | INVUS PUBLIC EQUITIES, L.P. | 10% | 30 Jul 2024 | Sale | 756,835 | 0.2209 | 167,185 | D |
30 Jul 2024 17:16 | GLYC | GLYCOMIMETICS INC | INVUS PUBLIC EQUITIES, L.P. | 10% | 29 Jul 2024 | Sale | 363,949 | 0.2353 | 85,637 | D |
30 Jul 2024 17:16 | GLYC | GLYCOMIMETICS INC | INVUS PUBLIC EQUITIES, L.P. | 10% | 26 Jul 2024 | Sale | 258,335 | 0.2417 | 62,440 | D |
24 Jun 2024 16:29 | GLYC | GLYCOMIMETICS INC | ROCK EDWIN | Chief Medical Officer | 21 Jun 2024 | Purchase | 115,000 | 0.2671 | 30,716 | D |
24 Jun 2024 16:29 | GLYC | GLYCOMIMETICS INC | ROCK EDWIN | Chief Medical Officer | 20 Jun 2024 | Purchase | 190,000 | 0.2532 | 48,108 | D |
20 Jun 2024 16:15 | GLYC | GLYCOMIMETICS INC | HAHN BRIAN M. | SVP Finance, CFO | 18 Jun 2024 | Purchase | 17,500 | 0.2477 | 4,335 | D |
25 Sep 2023 16:21 | GLYC | GLYCOMIMETICS INC | ROCK EDWIN | Chief Medical Officer | 22 Sep 2023 | Purchase | 30,403 | 1.38 | 41,956 | D |
25 Sep 2023 16:21 | GLYC | GLYCOMIMETICS INC | ROCK EDWIN | Chief Medical Officer | 21 Sep 2023 | Purchase | 35,000 | 1.38 | 48,300 | D |
18 May 2023 16:27 | GLYC | GLYCOMIMETICS INC | HAHN BRIAN M. | SVP Finance, CFO | 17 May 2023 | Sale | 3,700 | 1.95 | 7,215 | D |
11 May 2023 17:08 | GLYC | GLYCOMIMETICS INC | JUNIUS DANIEL M | Director | 10 May 2023 | Purchase | 30,000 | 1.56 | 46,800 | D |
09 May 2023 17:00 | GLYC | GLYCOMIMETICS INC | JOHNSON BRUCE S | SVP & Chief Commercial Officer | 08 May 2023 | Purchase | 13,500 | 1.57 | 21,195 | D |
28 Feb 2023 17:33 | GLYC | GLYCOMIMETICS INC | INVUS PUBLIC EQUITIES, L.P. | 10% | 24 Feb 2023 | Purchase | 100,000 | 1.7 | 170,000 | D |
23 Feb 2023 18:23 | GLYC | GLYCOMIMETICS INC | INVUS PUBLIC EQUITIES, L.P. | 10% | 23 Feb 2023 | Purchase | 200,000 | 1.7538 | 350,760 | D |
23 Feb 2023 18:23 | GLYC | GLYCOMIMETICS INC | INVUS PUBLIC EQUITIES, L.P. | 10% | 22 Feb 2023 | Purchase | 150,000 | 1.7933 | 268,995 | D |
23 Feb 2023 18:23 | GLYC | GLYCOMIMETICS INC | INVUS PUBLIC EQUITIES, L.P. | 10% | 21 Feb 2023 | Purchase | 50,000 | 1.85 | 92,500 | D |
17 Feb 2023 17:29 | GLYC | GLYCOMIMETICS INC | INVUS PUBLIC EQUITIES, L.P. | 10% | 17 Feb 2023 | Purchase | 200,000 | 1.705 | 341,000 | D |
17 Feb 2023 17:29 | GLYC | GLYCOMIMETICS INC | INVUS PUBLIC EQUITIES, L.P. | 10% | 16 Feb 2023 | Purchase | 315,266 | 1.6847 | 531,129 | D |
17 Feb 2023 17:29 | GLYC | GLYCOMIMETICS INC | INVUS PUBLIC EQUITIES, L.P. | 10% | 15 Feb 2023 | Purchase | 1,000,000 | 2.1558 | 2,155,800 | D |
13 Feb 2023 17:45 | GLYC | GLYCOMIMETICS INC | INVUS PUBLIC EQUITIES, L.P. | 10% | 09 Feb 2023 | Purchase | 11,451 | 3.2419 | 37,123 | D |
27 Jan 2023 17:15 | GLYC | GLYCOMIMETICS INC | SANDELL SCOTT D | 10% | 26 Jan 2023 | Sale | 1,351,092 | 3.1188 | 4,213,786 | I |
27 Jan 2023 17:15 | GLYC | GLYCOMIMETICS INC | SANDELL SCOTT D | 10% | 26 Jan 2023 | Sale | 1,648,908 | 3.1188 | 5,142,614 | I |
27 Jan 2023 17:15 | GLYC | GLYCOMIMETICS INC | SANDELL SCOTT D | 10% | 25 Jan 2023 | Sale | 293,645 | 3.2639 | 958,428 | I |
27 Jan 2023 17:15 | GLYC | GLYCOMIMETICS INC | SANDELL SCOTT D | 10% | 25 Jan 2023 | Sale | 358,371 | 3.2639 | 1,169,687 | I |
06 Jan 2023 18:35 | GLYC | GLYCOMIMETICS INC | SANDELL SCOTT D | 10% | 05 Jan 2023 | Sale | 32,139 | 2.7586 | 88,659 | I |
06 Jan 2023 18:35 | GLYC | GLYCOMIMETICS INC | SANDELL SCOTT D | 10% | 05 Jan 2023 | Sale | 39,223 | 2.7586 | 108,201 | I |
04 Jan 2023 17:26 | GLYC | GLYCOMIMETICS INC | SANDELL SCOTT D | 10% | 04 Jan 2023 | Sale | 45,930 | 2.9097 | 133,643 | I |
04 Jan 2023 17:26 | GLYC | GLYCOMIMETICS INC | SANDELL SCOTT D | 10% | 04 Jan 2023 | Sale | 56,054 | 2.9097 | 163,100 | I |
04 Jan 2023 17:26 | GLYC | GLYCOMIMETICS INC | SANDELL SCOTT D | 10% | 03 Jan 2023 | Sale | 78,730 | 2.9901 | 235,411 | I |
04 Jan 2023 17:26 | GLYC | GLYCOMIMETICS INC | SANDELL SCOTT D | 10% | 03 Jan 2023 | Sale | 96,084 | 2.9901 | 287,301 | I |
04 Jan 2023 17:26 | GLYC | GLYCOMIMETICS INC | SANDELL SCOTT D | 10% | 30 Dec 2022 | Sale | 54,645 | 3.02 | 165,028 | I |
04 Jan 2023 17:26 | GLYC | GLYCOMIMETICS INC | SANDELL SCOTT D | 10% | 30 Dec 2022 | Sale | 66,690 | 3.02 | 201,404 | I |
27 Dec 2022 18:41 | GLYC | GLYCOMIMETICS INC | ROCK EDWIN | Chief Medical Officer | 22 Dec 2022 | Purchase | 110,000 | 2.25 | 247,500 | D |
18 Nov 2022 16:01 | GLYC | GLYCOMIMETICS INC | JUNIUS DANIEL M | Director | 17 Nov 2022 | Purchase | 20,000 | 1.87 | 37,400 | D |
16 Nov 2022 16:26 | GLYC | GLYCOMIMETICS INC | ROCK EDWIN | Chief Medical Officer | 15 Nov 2022 | Purchase | 100,000 | 1.66 | 166,000 | D |
16 Nov 2022 16:26 | GLYC | GLYCOMIMETICS INC | ROCK EDWIN | Chief Medical Officer | 14 Nov 2022 | Purchase | 100,000 | 1.43 | 143,000 | D |
14 Nov 2022 16:13 | GLYC | GLYCOMIMETICS INC | HAHN BRIAN M. | SVP Finance, CFO | 11 Nov 2022 | Purchase | 20,000 | 1.06 | 21,200 | D |
14 Nov 2022 16:14 | GLYC | GLYCOMIMETICS INC | PEARSON TIMOTHY R | Director | 11 Nov 2022 | Purchase | 19,400 | 1.29 | 25,026 | D |
14 Nov 2022 16:11 | GLYC | GLYCOMIMETICS INC | MAGNANI JOHN L. | SVP of Research, CSO | 11 Nov 2022 | Purchase | 45,045 | 1.17 | 52,703 | D |
14 Nov 2022 16:13 | GLYC | GLYCOMIMETICS INC | SEMERJIAN HAROUT | Chief Executive Officer | 11 Nov 2022 | Purchase | 25,000 | 1.29 | 32,250 | D |
14 Nov 2022 16:04 | GLYC | GLYCOMIMETICS INC | GIRARD ARMAND | SVP, Chief Business Officer | 11 Nov 2022 | Purchase | 6,500 | 1.05 | 6,825 | D |
* D/I = Direct / Indirect
* 10% = Entity with 10% or higher ownership stake
* A = Amendment Filing (SEC Form 4/A)